HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NSAID Use By COVID Patients Not Associated With Adverse Outcomes Or Mortality – Danish Study

Executive Summary

Study of almost 10,000 COVID-19 patients finds use of ibuprofen and other NSAIDs does not increase chance of being hospitalized, admitted to the intensive care unit, or dying.

You may also be interested in...



Next Generation OTC Painkillers And Cough Syrup On Cards For German Switch Committee

Rx-to-OTC switches of the painkillers dexibuprofen and single-pill combinations of ibuprofen and paracetamol as well as the cough medicine levodropropizine, all for oral use, will be considered at the next German Expert Committee for Prescription meeting on 13 July.

OTC Advertisements In France To Carry COVID Warnings

French advertisements for OTC drugs that treat symptoms which could be associated with COVID-19 are set to carry new warning statements following a recommendation by the country's medicines regulator. 

‘Insufficient Evidence’ Ibuprofen Worsens COVID-19, Says UK Regulator

Review by MHRA advisory body finds no issue with ibuprofen use in COVID-19 patients and updates advice to recommend either paracetamol or ibuprofen to treat symptoms. 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150454

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel